Med Life (BSE:M) Research & Development: lei0 Mil (TTM As of Mar. 2026)


BSE:M Med Life SA BSE:M
90 GF Score
Price lei11.36
GF Value lei7.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Med Life Research & Development?

Med Life BSE:M +0.53% 90 Research & Development is lei0 Mil as of Mar. 2026. GuruFocus rates BSE:M with a GF Score™ of 90/100 and a GF Value™ of lei7.82 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Med Life's Research & Development for the three months ended in Mar. 2026 was lei0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was lei0 Mil.

Med Life  (BSE:M) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Med Life Research & Development Related Terms

Med Life Research & Development Historical Data

* Premium members only.

The historical data trend for Med Life's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Med Life Research & Development Chart

Med Life Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Med Life Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSE:M
90GF Score
Med Life SA BSE:M
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Med Life Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of lei0 Mil mean?
Med Life (BSE:M) has a Research & Development of lei0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Med Life and its competitors.
Is Med Life's Research & Development too high?
Med Life's current Research & Development is lei0 Mil. Overall, Med Life has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Research & Development compare to HCA and THC?
Med Life's Research & Development of lei0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Med Life and its competitors. Med Life's current Research & Development is lei0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (BSE:M) is currently considered Significantly Overvalued. The stock's GF Value™ is lei7.82, compared to a current price of lei11.36 — trading 45.3% above its estimated fair value. The current Research & Development is lei0 Mil. Med Life's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Med Life (BSE:M), the current Research & Development is lei0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Med Life (BSE:M) Overvalued in 2026?

Based on GuruFocus' analysis, Med Life stock appears to be overvalued. The current stock price of lei11.36 is trading 45.3% above its estimated GF Value™ of lei7.82. GuruFocus considers Med Life to be Significantly Overvalued.

Key valuation signals for BSE:M:

  • Research & Development: lei0 Mil
  • GF Value™: lei7.82 vs. price of lei11.36 (45.3% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the BSE:M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Med Life Business Description

Other Exchanges 0RO5:UKO0C:Germany
Address Calea Grivitei, No. 365, District 1, Bucharest, ROU
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
90GF Score

Get the complete analysis for BSE:M

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei11.36
Price
lei7.82
GF Value